Format

Send to

Choose Destination
Curr Pain Headache Rep. 2019 Mar 14;23(5):29. doi: 10.1007/s11916-019-0768-y.

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.

Author information

1
Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA. iurits@bidmc.harvard.edu.
2
Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA.
3
Georgetown University School of Medicine, Washington, DC, USA.
4
Creighton University School of Medicine-Phoenix Regional Campus, Phoenix, AZ, USA.
5
Department of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
6
Valley Anesthesiology and Pain Consultants, Phoenix, AZ, USA.
7
University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.
8
Creighton University School of Medicine, Omaha, NE, USA.

Abstract

PURPOSE OF REVIEW:

The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist.

RECENT FINDINGS:

Despite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers. CGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway.

KEYWORDS:

Calcitonin gene receptor peptide (CGRP) antagonist; Chronic migraines; Episodic migraines; Erenumab

PMID:
30874961
DOI:
10.1007/s11916-019-0768-y

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center